We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Dose of competition

17 June 2013 By Reynolds Holding

The U.S. justices allowed antitrust suits against pharmaceutical firms like Solvay that pay rivals not to offer cheaper generic medicines. The practice might still pass muster, but the anticompetitive effects are clear. Drug makers may end up charging consumers less.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)